(Circulation. 1999;99:2590-2597.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Protease-Activated Receptor-2 Involvement in Hypotension in Normal and Endotoxemic Rats In Vivo
From the Dipartimento di Farmacologia Sperimentale, Naples, Italy (C.C., M.B., R.S., G.C.); Dipartimento di Scienze Farmaceutiche, Penta (Sa), Italy (A.P.); the School of Biology and Biochemistry, Queen's University of Belfast, Medical Biology Centre, Belfast, UK (B.W., P.H.); and Clinical Sciences Research Centre, St Bartholomew's, and the Royal London School of Medicine and Dentistry, London, UK (A.C., S.K., G.L.H.).
Correspondence to Professor Giuseppe Cirino, PhD, Dipartimento di Farmacologia Sperimentale, Via Domenico Montesano 49, 80131 Naples, Italy. E-mail cirino{at}cds.unina.it
Background—The protease-activated receptor-2 (PAR-2) is expressed by vascular endothelial cells and upregulated by lipopolysaccharide (LPS) in vitro. PAR-2 is activated by a tethered ligand created after proteolytic cleavage by trypsin or experimentally by a synthetic agonist peptide (PAR-2AP) corresponding to the new amino terminus of the tethered ligand.
Methods and Results—Intravenous administration of PAR-2AP (0.1, 0.3, and 1 mg/kg) to rats caused a dose-dependent hypotension. A scrambled peptide was without effect. A specific trypsin inhibitor, biotin–SGKR-chloromethylketone, inhibited trypsin-induced hypotension but not that stimulated by PAR-2AP. In animals treated with LPS 20 hours earlier, we found an increased sensitivity to trypsin and PAR-2AP in the hypotensive response. In particular, PAR-2AP caused hypotension at a low concentration of 30 ng/kg. Moreover, PAR-2 was immunolocalized to endothelial and smooth muscle cells in aorta and jugular vein in LPS-treated rats, and increased levels of PAR-2 mRNA were shown by reverse transcription–polymerase chain reaction analysis.
Conclusions—Our findings suggest that PAR-2 is important in the regulation of blood pressure in vivo. A functional upregulation of PAR-2 by LPS was demonstrated by the activity of concentrations of PAR-2AP that were inactive in normal animals. We conclude that PAR-2 may play an important role in the hypotension associated with endotoxic shock and may represent a new therapeutic target.
Key Words: receptors • trypsin • endotoxemia • hypotension • shock
This article has been cited by other articles:
 |
|
 |
|
  P. Rallabhandi, Q. M. Nhu, V. Y. Toshchakov, W. Piao, A. E. Medvedev, M. D. Hollenberg, A. Fasano, and S. N. Vogel Analysis of Proteinase-activated Receptor 2 and TLR4 Signal Transduction: A NOVEL PARADIGM FOR RECEPTOR COOPERATIVITY J. Biol. Chem., September 5, 2008; 283(36): 24314 - 24325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Jiang, A. Zatta, H. Kin, N. Wang, J. G. Reeves, J. Mykytenko, J. Deneve, Z.-Q. Zhao, R. A. Guyton, and J. Vinten-Johansen PAR-2 activation at the time of reperfusion salvages myocardium via an ERK1/2 pathway in in vivo rat hearts Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2845 - H2852. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Moussa, J. Apostolopoulos, P. Davenport, J. Tchongue, and P. G. Tipping Protease-Activated Receptor-2 Augments Experimental Crescentic Glomerulonephritis Am. J. Pathol., September 1, 2007; 171(3): 800 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hirano The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 27 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Roviezzo, M. Bucci, V. Brancaleone, A. Di Lorenzo, P. Geppetti, S. Farneti, L. Parente, G. Lungarella, S. Fiorucci, and G. Cirino Proteinase-Activated Receptor-2 Mediates Arterial Vasodilation in Diabetes Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2349 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Steinhoff, J. Buddenkotte, V. Shpacovitch, A. Rattenholl, C. Moormann, N. Vergnolle, T. A. Luger, and M. D. Hollenberg Proteinase-Activated Receptors: Transducers of Proteinase-Mediated Signaling in Inflammation and Immune Response Endocr. Rev., February 1, 2005; 26(1): 1 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Steinberg The Cardiovascular Actions of Protease-Activated Receptors Mol. Pharmacol., January 1, 2005; 67(1): 2 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Oshiro, H. Otani, Y. Yagi, S. Fukuhara, and C. Inagaki Protease-Activated Receptor-2-Mediated Inhibition for Ca2+ Response to Lipopolysaccharide in Guinea Pig Tracheal Epithelial Cells Am. J. Respir. Cell Mol. Biol., June 1, 2004; 30(6): 886 - 892. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Napoli, F de Nigris, J L Wallace, M D Hollenberg, G Tajana, G De Rosa, V Sica, and G Cirino Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions J. Clin. Pathol., May 1, 2004; 57(5): 513 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. S. OSSOVSKAYA and N. W. BUNNETT Protease-Activated Receptors: Contribution to Physiology and Disease Physiol Rev, April 1, 2004; 84(2): 579 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Lan, G. A. Stewart, R. G. Goldie, and P. J. Henry Altered expression and in vivo lung function of protease-activated receptors during influenza A virus infection in mice Am J Physiol Lung Cell Mol Physiol, February 1, 2004; 286(2): L388 - L398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird Thrombin and Phenotypic Modulation of the Endothelium Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 41 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cicala, S. Morello, V. Vellecco, B. Severino, L. Sorrentino, and G. Cirino Basal nitric oxide modulates vascular effects of a peptide activating protease-activated receptor 2 Cardiovasc Res, November 1, 2003; 60(2): 431 - 437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Robin, R. Kharbanda, P. Mclean, R. Campbell, and P. Vallance Protease-Activated Receptor 2-Mediated Vasodilatation in Humans In Vivo: Role of Nitric Oxide and Prostanoids Circulation, February 25, 2003; 107(7): 954 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Landis Aprotinin: Antithrombotic and Vasoactive Mechanisms of Action Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 307 - 312. [Abstract] [PDF]
|
|
|
|
|
|
N. Cenac, A.-M. Coelho, C. Nguyen, S. Compton, P. Andrade-Gordon, W. K. MacNaughton, J. L. Wallace, M. D. Hollenberg, N. W. Bunnett, R. Garcia-Villar, et al. Induction of Intestinal Inflammation in Mouse by Activation of Proteinase-Activated Receptor-2 Am. J. Pathol., November 1, 2002; 161(5): 1903 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Milia, M. B. Salis, T. Stacca, A. Pinna, P. Madeddu, M. Trevisani, P. Geppetti, and C. Emanueli Protease-Activated Receptor-2 Stimulates Angiogenesis and Accelerates Hemodynamic Recovery in a Mouse Model of Hindlimb Ischemia Circ. Res., August 23, 2002; 91(4): 346 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Macfarlane, M. J. Seatter, T. Kanke, G. D. Hunter, and R. Plevin Proteinase-Activated Receptors Pharmacol. Rev., June 1, 2001; 53(2): 245 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhattacharya, G. F. Smith, and M. L. Cohen Effect of LY287045, a Thrombin/Trypsin Inhibitor, on Thrombin and Trypsin-Induced Aortic Contraction and Relaxation J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 573 - 581. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. R. Lindner, M. L. Kahn, S. R. Coughlin, G. R. Sambrano, E. Schauble, D. Bernstein, D. Foy, A. Hafezi-Moghadam, and K. Ley Delayed Onset of Inflammation in Protease-Activated Receptor-2-Deficient Mice J. Immunol., December 1, 2000; 165(11): 6504 - 6510. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Napoli, C. Cicala, J. L. Wallace, F. de Nigris, V. Santagada, G. Caliendo, F. Franconi, L. J. Ignarro, and G. Cirino From the Cover: Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart PNAS, March 28, 2000; 97(7): 3678 - 3683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Napoli, F. De Nigris, C. Cicala, J. L. Wallace, G. Caliendo, M. Condorelli, V. Santagada, and G. Cirino Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning Am J Physiol Heart Circ Physiol, June 1, 2002; 282(6): H2004 - H2010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. McLean, D. Aston, D. Sarkar, and A. Ahluwalia Protease-Activated Receptor-2 Activation Causes EDHF-Like Coronary Vasodilation: Selective Preservation in Ischemia/Reperfusion Injury: Involvement of Lipoxygenase Products, VR1 Receptors, and C-Fibers Circ. Res., March 8, 2002; 90(4): 465 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Hamilton, A. G. Frauman, and T. M. Cocks Increased Expression of Protease-Activated Receptor-2 (PAR2) and PAR4 in Human Coronary Artery by Inflammatory Stimuli Unveils Endothelium-Dependent Relaxations to PAR2 and PAR4 Agonists Circ. Res., July 6, 2001; 89(1): 92 - 98. [Abstract] [Full Text] [PDF]
|
|